LL-37 has no FDA-approved human dose for any indication.

Introduction LL-37 is a 37-amino-acid antimicrobial peptide, the C-terminal fragment of the human cathelicidin antimicrobial protein (hCAP18) encoded by the CAMP gene. It’s the…

Most patients on liraglutide eventually consider switching. The reasons vary. Daily injections get tiring compared with weekly options.

Liraglutide is a peptide. Peptides denature with heat and crystallize with freezing.

The side effect profile of liraglutide is dominated by gastrointestinal symptoms.

Liraglutide produces an average of about 8% weight loss at 56 weeks in clinical trials. That figure comes from SCALE (Pi-Sunyer et al.

Liraglutide is a once-daily injectable GLP-1 receptor agonist that mimics a gut hormone called glucagon-like peptide-1.

Liraglutide turned 16 years old in 2026.

Liraglutide has two FDA labels. Saxenda for chronic weight management at doses up to 3 mg daily.